LGND News and Press, Ligand Pharmaceuticals Incorporated From 07/29/21

Ligand Pharmaceuticals (NASDAQ:LGND): Q2 Non-GAAP EPS of $1.63 beats by $0.27; GAAP EPS of $1.79 beats by $1.05. Revenue of $84.7M (+104.5% Y/Y) beats by $13.29M. Ligand now expects full-year 2021 total revenues to be between $265 million and $275 million (prior $291 million) vs. consensus of...

Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms PR Newswire PALO ALTO, Calif. , July 28, 2021 /PRNewswire/ -- Landing A...

Ligand expects to receive $7 million in milestone payments Rylaze for the treatment of ALL or LBL utilizes Ligand’s Pelican Expression Technology™ Platform Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced Jazz Pharmaceuticals plc (NASDAQ: ...

VAXNEUVANCE, formerly V114, utilizes Ligand’s CRM197 carrier protein (PeliCRM™) Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Merck has received approval from the U.S. Food and Drug Administration (FDA) for VAXNEUVANCE TM , a...

Ligand helps other biopharma drug developers with its various platforms. The company earns royalties, contractual fees, and from sales of Captisol material. 2021 is a pivotal year in terms of revenue for this historically highly shorted stock. For further details see: Li...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three and six months ended June 30, 2021 after the close of the U.S. financial markets on Thursday, July 29, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern tim...

Ligand Pharmaceuticals (LGND) announces the appointment of Jennifer Cochran to the company's board of directors.Cochran is the Shriram Chair of the Department of Bioengineering at Stanford University.She has founded multiple companies in the fields of oncology and regenerative ...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Jennifer Cochran, Ph.D. to the Company's Board of Directors. Dr. Cochran is the Shriram Chair of the Department of Bioengineering at Stanford U...

COLUMBUS, Ohio, June 28, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, today announced that enrollment has been completed for its Phase ...

The FDA has accepted with priority review the BLA for Johnson & Johnson (JNJ) Janssen unit's ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma.The PDUFA date is November 29, 2021.Janssen began a rolling submission of the CAR-T therapy in December.J&a...